Poudel A, Palaian S, Shankar P R, Jayasekera J, Izham M I
Drug Information and Pharmacovigilance Center, Manipal Teaching Hospital, Pokhara, Nepal.
Kathmandu Univ Med J (KUMJ). 2008 Jul-Sep;6(23):399-405. doi: 10.3126/kumj.v6i3.1723.
A large proportion of drugs available are of little importance in terms of fulfilling primary healthcare needs. Combination drugs increase the risk of side effects, lead to an ineffective dosage and liability to abuse and may also needlessly increase the cost. Drug combinations make it more difficult to find the causative agent responsible for the adverse reactions. In many cases their stability is doubtful, reducing the efficacy of many preparations. The Fifteenth WHO model list of essential medicines (March 2007) contains only 25 approved fixed dose combinations, whereas in Nepal, there are innumerable examples of irrational drug combinations, which are easily available and can be bought even without a prescription. A system of screening the drug combinations that are already licensed and available in the market is implemented in many developed and developing countries. Rational combinations can be of immense help to the health care system. These combinations may improve the quality of life for many and increase compliance. But irrational fixed dose combination products can be equally harmful.
现有很大一部分药物在满足初级医疗保健需求方面作用不大。复方药物会增加副作用风险,导致剂量无效、易于滥用,还可能无端增加成本。药物组合使得找出不良反应的致病因素更加困难。在许多情况下,它们的稳定性存疑,会降低许多制剂的疗效。世界卫生组织第十五版基本药物示范清单(2007年3月)仅包含25种获批的固定剂量复方制剂,而在尼泊尔,不合理药物组合的例子数不胜数,这些组合很容易买到,甚至无需处方就能购买。许多发达国家和发展中国家都实施了对市场上已获许可并在售的药物组合进行筛查的制度。合理的组合对医疗保健系统可能有极大帮助。这些组合可能会改善许多人的生活质量并提高依从性。但不合理的固定剂量复方产品可能同样有害。